Cargando…
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
The anti-proliferative and anti-angiogenic properties of the endogenous oestrogen metabolite, 2-methoxyoestradiol (2-MeOE2), are enhanced in a series of sulphamoylated derivatives of 2-MeOE2. To investigate possible mechanisms of resistance to these compounds, a cell line, A2780.140, eightfold less...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658539/ https://www.ncbi.nlm.nih.gov/pubmed/19156141 http://dx.doi.org/10.1038/sj.bjc.6604873 |
_version_ | 1782165639276789760 |
---|---|
author | Day, J M Foster, P A Tutill, H J Newman, S P Ho, Y T Leese, M P Potter, B V L Reed, M J Purohit, A |
author_facet | Day, J M Foster, P A Tutill, H J Newman, S P Ho, Y T Leese, M P Potter, B V L Reed, M J Purohit, A |
author_sort | Day, J M |
collection | PubMed |
description | The anti-proliferative and anti-angiogenic properties of the endogenous oestrogen metabolite, 2-methoxyoestradiol (2-MeOE2), are enhanced in a series of sulphamoylated derivatives of 2-MeOE2. To investigate possible mechanisms of resistance to these compounds, a cell line, A2780.140, eightfold less sensitive to the 3,17-O,O-bis-sulphamoylated derivative, STX140, was derived from the A2780 ovarian cancer cell line by dose escalation. Other cell lines tested did not develop STX140 resistance. RT–PCR and immunoblot analysis demonstrated that breast cancer resistance protein (BCRP) expression is dramatically increased in A2780.140 cells. The cells are cross-resistant to the most structurally similar bis-sulphamates, and to BCRP substrates, mitoxantrone and doxorubicin; but they remain sensitive to taxol, an MDR1 substrate, and to all other sulphamates tested. Sensitivity can be restored using a BCRP inhibitor, and this pattern of resistance is also seen in a BCRP-expressing MCF-7-derived cell line, MCF-7.MR. In mice bearing wild-type (wt) and BCRP-expressing tumours on either flank, both STX140 and mitoxantrone inhibited the growth of the MCF-7wt xenografts, but only STX140 inhibited growth of the MCF-7.MR tumours. In conclusion, STX140, a promising orally bioavailable anti-cancer agent in pre-clinical development, is highly efficacious in BCRP-expressing xenografts. This is despite an increase in BCRP expression in A2780 cells in vitro after chronic dosing with STX140. |
format | Text |
id | pubmed-2658539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-26585392010-02-10 BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure Day, J M Foster, P A Tutill, H J Newman, S P Ho, Y T Leese, M P Potter, B V L Reed, M J Purohit, A Br J Cancer Translational Therapeutics The anti-proliferative and anti-angiogenic properties of the endogenous oestrogen metabolite, 2-methoxyoestradiol (2-MeOE2), are enhanced in a series of sulphamoylated derivatives of 2-MeOE2. To investigate possible mechanisms of resistance to these compounds, a cell line, A2780.140, eightfold less sensitive to the 3,17-O,O-bis-sulphamoylated derivative, STX140, was derived from the A2780 ovarian cancer cell line by dose escalation. Other cell lines tested did not develop STX140 resistance. RT–PCR and immunoblot analysis demonstrated that breast cancer resistance protein (BCRP) expression is dramatically increased in A2780.140 cells. The cells are cross-resistant to the most structurally similar bis-sulphamates, and to BCRP substrates, mitoxantrone and doxorubicin; but they remain sensitive to taxol, an MDR1 substrate, and to all other sulphamates tested. Sensitivity can be restored using a BCRP inhibitor, and this pattern of resistance is also seen in a BCRP-expressing MCF-7-derived cell line, MCF-7.MR. In mice bearing wild-type (wt) and BCRP-expressing tumours on either flank, both STX140 and mitoxantrone inhibited the growth of the MCF-7wt xenografts, but only STX140 inhibited growth of the MCF-7.MR tumours. In conclusion, STX140, a promising orally bioavailable anti-cancer agent in pre-clinical development, is highly efficacious in BCRP-expressing xenografts. This is despite an increase in BCRP expression in A2780 cells in vitro after chronic dosing with STX140. Nature Publishing Group 2009-02-10 2009-01-20 /pmc/articles/PMC2658539/ /pubmed/19156141 http://dx.doi.org/10.1038/sj.bjc.6604873 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Translational Therapeutics Day, J M Foster, P A Tutill, H J Newman, S P Ho, Y T Leese, M P Potter, B V L Reed, M J Purohit, A BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title | BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title_full | BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title_fullStr | BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title_full_unstemmed | BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title_short | BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure |
title_sort | bcrp expression does not result in resistance to stx140 in vivo, despite the increased expression of bcrp in a2780 cells in vitro after long-term stx140 exposure |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658539/ https://www.ncbi.nlm.nih.gov/pubmed/19156141 http://dx.doi.org/10.1038/sj.bjc.6604873 |
work_keys_str_mv | AT dayjm bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT fosterpa bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT tutillhj bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT newmansp bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT hoyt bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT leesemp bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT potterbvl bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT reedmj bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure AT purohita bcrpexpressiondoesnotresultinresistancetostx140invivodespitetheincreasedexpressionofbcrpina2780cellsinvitroafterlongtermstx140exposure |